Samil Pharmaceutical Major Shareholder Ownership Change Report, Minor Increase Neutral to Shareholder Value

On June 10, 2026, Samil Pharmaceutical's major shareholder and related parties Heo Yul and Heo I-jeong acquired 2,561 and 2,543 shares respectively through open market purchases, increasing total ownership from 25.93% to 25.96%, a 0.02% increase.
This change is a minor open market purchase with no capital dilution or fundraising purpose, thus having negligible impact on shareholder value.
From a governance perspective, the small increase in the founding family's stake does not indicate any change in control or added governance risk.
[AI Summary]The slight increase in Samil Pharmaceutical's major shareholder stake is insignificant and a routine market transaction, neutral to shareholder value. No capital changes or strategic shifts occur, so no material impact on investors.